Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

For An Ultra-High-Priced Drug, Alnylam Brings A New Idea

20 Nov 2019

• By Jessica Merrill

Stack-100 bills

Related Content

Alnylam Wins FDA Approval For Givlaari, Its Second RNAi Drug

20 Nov 2019

Alnylam Ramps Up Commercial Planning For Givosiran Based On Phase III Data

06 Mar 2019

Related Companies

Alnylam Pharmaceuticals Inc.

Additional Topics

United States Rare Diseases Pricing Strategies Reimbursement Market Access Approvals Policy Commercial BioPharmaceutical

More from Rare Diseases

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.